Prevalence and trends in polypharmacy and excessive polypharmacy: a retrospective national database analysis (2012-2021).

Aging Belgium Insurance claim reporting Polypharmacy

Journal

International journal of clinical pharmacy

ISSN: 2210-7711

Titre abrégé: Int J Clin Pharm

Pays: Netherlands

ID NLM: 101554912

Informations de publication

Date de publication:
05 May 2024

Historique:

received: 10 08 2023

accepted: 30 03 2024

medline: 5 5 2024

pubmed: 5 5 2024

entrez: 5 5 2024

Statut: aheadofprint

Résumé

Polypharmacy is a growing concern, impacting patient safety and healthcare costs. Monitoring its prevalence and temporal trends is essential for effective healthcare management. This study aimed to determine prevalence and trends of polypharmacy and excessive polypharmacy in Belgium. Utilizing a federal claims database, medication data were analyzed from 2012 to 2021. Polypharmacy (≥ 5 medications) and excessive polypharmacy (≥ 10 medications) were evaluated, with prevalence calculated per 1000 inhabitants, and reported per year, age group and region. Linear regression estimated the impact of age and year on polypharmacy prevalence. In 2021, polypharmacy and excessive polypharmacy were reported in 135/1000 and 31/1000 Belgians respectively. Prevalence of both increased steadily from 2012 to 2021, with excessive polypharmacy rising more prominently. Among adults aged ≥ 65 years, prevalence rates were higher, with polypharmacy at 434/1000 and excessive polypharmacy at 106/1000. Regional variations were observed, with prevalence highest in the Walloons region. Patient age and year (2012-2021) were associated with both polypharmacy and excessive polypharmacy (p < 0.001). We observed increases in polypharmacy and excessive polypharmacy over a decade in Belgium, particularly among older adults. Efforts to monitor, manage, and optimize medication use are imperative to ensure safe and effective healthcare delivery.

Sections du résumé

BACKGROUND BACKGROUND

Polypharmacy is a growing concern, impacting patient safety and healthcare costs. Monitoring its prevalence and temporal trends is essential for effective healthcare management.

AIM OBJECTIVE

This study aimed to determine prevalence and trends of polypharmacy and excessive polypharmacy in Belgium.

METHOD METHODS

Utilizing a federal claims database, medication data were analyzed from 2012 to 2021. Polypharmacy (≥ 5 medications) and excessive polypharmacy (≥ 10 medications) were evaluated, with prevalence calculated per 1000 inhabitants, and reported per year, age group and region. Linear regression estimated the impact of age and year on polypharmacy prevalence.

RESULTS RESULTS

In 2021, polypharmacy and excessive polypharmacy were reported in 135/1000 and 31/1000 Belgians respectively. Prevalence of both increased steadily from 2012 to 2021, with excessive polypharmacy rising more prominently. Among adults aged ≥ 65 years, prevalence rates were higher, with polypharmacy at 434/1000 and excessive polypharmacy at 106/1000. Regional variations were observed, with prevalence highest in the Walloons region. Patient age and year (2012-2021) were associated with both polypharmacy and excessive polypharmacy (p < 0.001).

CONCLUSION CONCLUSIONS

We observed increases in polypharmacy and excessive polypharmacy over a decade in Belgium, particularly among older adults. Efforts to monitor, manage, and optimize medication use are imperative to ensure safe and effective healthcare delivery.

Identifiants

DOI: 10.1007/s11096-024-01735-9 PMID: 38704778

pubmed: 38704778

doi: 10.1007/s11096-024-01735-9

pii: 10.1007/s11096-024-01735-9

doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

Informations de copyright

Références

Hellemans L, Nuyts S, Hias J, et al. Polypharmacy and excessive polypharmacy in community-dwelling middle aged and aged adults between 2011 and 2015. Int J Clin Pract. 2021;75(4):e13942.

doi: 10.1111/ijcp.13942 pubmed: 33340210

Hias J, Hellemans L, Nuyts S, et al. Predictors for unplanned hospital admissions in community dwelling adults: a dynamic cohort study. Res Social Adm Pharm. 2023;19(11):1432–9.

doi: 10.1016/j.sapharm.2023.07.004 pubmed: 37573152

Wehling M. Guideline-driven polypharmacy in elderly, multimorbid patients is basically flawed: there are almost no guidelines for these patients. J Am Geriatr Soc. 2011;59(2):376–7.

doi: 10.1111/j.1532-5415.2011.03252.x pubmed: 21314663

Wauters M, Elseviers M, Vaes B, et al. Too many, too few, or too unsafe? Impact of inappropriate prescribing on mortality, and hospitalization in a cohort of community-dwelling oldest old. Br J Clin Pharmacol. 2016;82(5):1382–92.

doi: 10.1111/bcp.13055 pubmed: 27426227 pmcid: 5061799

Petrovic M, Somers A, Onder G. Optimization of geriatric pharmacotherapy: role of multifaceted cooperation in the hospital setting. Drugs Aging. 2016;33(3):179–88.

doi: 10.1007/s40266-016-0352-7 pubmed: 26884392

Onder G, van der Cammen TJ, Petrovic M, et al. Strategies to reduce the risk of iatrogenic illness in complex older adults. Age Ageing. 2013;42(3):284–91.

doi: 10.1093/ageing/aft038 pubmed: 23537588

Marcum ZA, Amuan ME, Hanlon JT, et al. Prevalence of unplanned hospitalizations caused by adverse drug reactions in older veterans. J Am Geriatr Soc. 2012;60(1):34–41.

doi: 10.1111/j.1532-5415.2011.03772.x pubmed: 22150441

Leendertse AJ, Egberts AC, Stoker LJ, et al. Frequency of and risk factors for preventable medication-related hospital admissions in the Netherlands. Arch Intern Med. 2008;168(17):1890–6.

pubmed: 18809816

Van der Linden L, Hias J, Walgraeve K, et al. Guideline-directed medical therapies for heart failure with a reduced ejection fraction in older adults: a narrative review on efficacy. Saf Timeliness Drugs Aging. 2023;40(8):691–702.

doi: 10.1007/s40266-023-01046-0

Scott IA, Hilmer SN, Reeve E, et al. Reducing inappropriate polypharmacy: the process of deprescribing. JAMA Intern Med. 2015;175(5):827–34.

doi: 10.1001/jamainternmed.2015.0324 pubmed: 25798731

Hellemans L, Hias J, Walgraeve K, et al. Deprescribing in geriatric inpatients is associated with a lower readmission risk: a case control study. Int J Clin Pharm. 2020;42(5):1374–8.

doi: 10.1007/s11096-020-01091-4 pubmed: 32803558

Bulow C, Clausen SS, Lundh A, et al. Medication review in hospitalised patients to reduce morbidity and mortality. Cochrane Database Syst Rev. 2023;1(1):CD008986. https://doi.org/10.1002/14651858.CD008986 .

doi: 10.1002/14651858.CD008986 pubmed: 36688482

Van der Linden L. Improving medication use in older adults: looking back to move forward. Lancet Healthy Longev. 2023;4(6):e246. https://doi.org/10.1016/S2666-7568(23)00082-X .

doi: 10.1016/S2666-7568(23)00082-X pubmed: 37269862

Thillainadesan J, Gnjidic D, Green S, et al. Impact of deprescribing interventions in older hospitalised patients on prescribing and clinical outcomes: a systematic review of randomised trials. Drugs Aging. 2018;35(4):303–19.

doi: 10.1007/s40266-018-0536-4 pubmed: 29541966

Belgian Intermutualistic Agency. ZorgAtlas 2023. https://atlas.ima-aim.be/databanken/?rw=1&lang=nl . Accessed 01 Aug 2023.

STATBel - Belgium in Figures. Bevolkingsvooruitzichten. 2017. http://statbel.fgov.be/sites/default/files/files/documents/bevolking/5.8%20Bevolkingsvooruitzichten/bestanden/FOR_POP1660_11440_N%20print.pdf . Accessed 01 Aug 2023.

Daunt R, Curtin D, O’Mahony D. Polypharmacy stewardship: a novel approach to tackle a major public health crisis. Lancet Healthy Longev. 2023;4(5):e228–35. https://doi.org/10.1016/S2666-7568(23)00036-3 .

doi: 10.1016/S2666-7568(23)00036-3 pubmed: 37030320

American Geriatrics Society Expert Panel on the Care of Older Adults with Multimorbidity. Guiding principles for the care of older adults with multimorbidity: an approach for clinicians: American Geriatrics Society Expert Panel on the Care of Older Adults with Multimorbidity. J Am Geriatr Soc. 2012;60(10):E1-E25. https://doi.org/10.1111/j.1532-5415.2012.04188.x .

Morgan SG, Cunningham CM, Hanley GE. Individual and contextual determinants of regional variation in prescription drug use: an analysis of administrative data from British Columbia. PLoS ONE. 2010;5(12):e15883. https://doi.org/10.1371/journal.pone.0015883 .

doi: 10.1371/journal.pone.0015883 pubmed: 21209960 pmcid: 3012101

Rankin A, Cadogan CA, Patterson SM, et al. Interventions to improve the appropriate use of polypharmacy for older people. Cochrane Database Syst Rev. 2018;9(9):CD008165. https://doi.org/10.1002/14651858.CD008165 .

doi: 10.1002/14651858.CD008165 pubmed: 30175841

Capiau A, Foubert K, Van der Linden L, et al. Medication counselling in older patients prior to hospital discharge: a systematic review. Drugs Aging. 2020;37(9):635–55.

doi: 10.1007/s40266-020-00780-z pubmed: 32643062

Van der Linden L, Hias J, Walgraeve K, et al. Clinical pharmacy services in older inpatients: an evidence-based review. Drugs Aging. 2020;37(3):161–74.

doi: 10.1007/s40266-019-00733-1 pubmed: 31919802

Tan ECK, Sluggett JK, Johnell K, et al. Research priorities for optimizing geriatric pharmacotherapy: an international consensus. J Am Med Dir Assoc. 2018;19(3):193–9.

doi: 10.1016/j.jamda.2017.12.002 pubmed: 29361432